Key result
18F-FDG PET/CT effectively characterizes, stages, and evaluates treatment response in primary mediastinal large B-cell lymphoma.
Why the study?
Optimal management strategies for PMLBCL remain debated, and distinguishing viable disease from residual fibrotic or inflammatory tissue after therapy remains a major clinical challenge.
What is the role of [18F]FDG PET/CT in the management, staging, and restaging of primary mediastinal large B-cell lymphoma?
Design
Review
Authors
Loading...
Supports [18F]FDG PET/CT integration in PMLBCL pathways; leaves open need for prospective validation of outcome impact.
What is the role of [18F]FDG PET/CT in the management, staging, and restaging of primary mediastinal large B-cell lymphoma?
[18F]FDG PET/CT is a pivotal tool for staging, restaging, and distinguishing viable disease from residual fibrotic mass in patients with primary mediastinal large B-cell lymphoma.
Nappi et al. (2025) conducted a review in Primary mediastinal large B-cell lymphoma (PMLBCL). [18F]FDG PET/CT was evaluated. [18F]FDG PET/CT serves as a principal tool in characterizing, staging, and evaluating treatment response in primary mediastinal large B-cell lymphoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: